AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11270999 — intervention group
Group type: COMPARATOR
Intervention: Imported 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Number of subjects: 20
Study 11270999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both domestic and imported capsules
Number of subjects: 20
Study 8889077 — intervention group
Group type: EXPERIMENTAL
Intervention: Community residence label with disturbed behaviour
Number of subjects: 488
Study 8889077 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric hospital label with disturbed behaviour
Number of subjects: 488
Study 8889077 — intervention group
Group type: COMPARATOR
Intervention: Community residence label with control behaviour
Number of subjects: 488
Study 8889077 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric hospital label with control behaviour
Number of subjects: 488
Study 1478035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg three times daily for 3 months)
Number of subjects: 30
Study 6363219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol
Number of subjects: 27
Study 6363219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31691531 — intervention group
Group type: COMPARATOR
Intervention: IBT‐alone
Number of subjects: 150
Study 31691531 — intervention group
Group type: EXPERIMENTAL
Intervention: IBT‐liraglutide
Number of subjects: 150
Study 31691531 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent (IBT-liraglutide + portion-controlled diet)
Number of subjects: 150
Study 29506562 — intervention group
Group type: EXPERIMENTAL
Intervention: BetaMe programme (comprehensive self-management programme delivered by mobile and web-based technologies)
Number of subjects: 430
Study 29506562 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430
Study 26599983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective β-blockers (NSBBs)
Number of subjects: 1198
Study 24943829 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate Schools program (six lesson computer‐based program)
Number of subjects: 1734
Study 24943829 — intervention group
Group type: COMPARATOR
Intervention: Usual health classes including drug education
Number of subjects: 1734
Study 22770996 — intervention group
Group type: EXPERIMENTAL
Intervention: High body checking group (focus on typically disliked body parts)
Number of subjects: 234
Study 22770996 — intervention group
Group type: COMPARATOR
Intervention: Low body checking group (focus on bodies as a whole with neutral terms)
Number of subjects: 234
Study 22770996 — intervention group
Group type: EXPERIMENTAL
Intervention: High body checking group
Number of subjects: 234
Study 22770996 — intervention group
Group type: COMPARATOR
Intervention: Low body checking group
Number of subjects: 234
Study 20220611 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise program (3 times per week for 70 minutes per session over 24 weeks)
Number of subjects: 69
Study 20220611 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 69
Study 17451612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy/meditation intervention (4 one-hour sessions)
Number of subjects: 25
Study 17451612 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (3 months before receiving treatment)
Number of subjects: 25
Study 16463837 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide 50%/fentanyl (n = 22)
Number of subjects: 48
Study 16463837 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl/air/oxygen (n = 26)
Number of subjects: 48
Study 16463837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (n = 23)
Number of subjects: 48
Study 16463837 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (n = 25)
Number of subjects: 48
Study 12424105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 2 mg/kg of [13C]Phe
Number of subjects: 18
Study 10503580 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 0
Study 10503580 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study 8696702 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Exposure Control (AEC) technique
Number of subjects: 329
Study 8696702 — intervention group
Group type: COMPARATOR
Intervention: Manual Exposure Control (MEC) technique
Number of subjects: 329
Study 1714885 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 150 mg twice daily
Number of subjects: 24
Study 6110863 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol
Number of subjects: 20
Study 6110863 — intervention group
Group type: COMPARATOR
Intervention: castor oil
Number of subjects: 20
Study 30875313 — intervention group
Group type: COMPARATOR
Intervention: NP (no cavity preparation, control)
Number of subjects: 70
Study 30875313 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD3 (3.0-mm-deep MOD preparation, not restored)
Number of subjects: 70
Study 30875313 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD3R (3.0-mm-deep MOD preparation restored with RBC)
Number of subjects: 70
Study 30875313 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD5 (5.0-mm-deep MOD preparation, not restored)
Number of subjects: 70
Study 30875313 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD5R (5.0-mm-deep MOD preparation restored with RBC)
Number of subjects: 70
Study 30875313 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD3RC (3.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Number of subjects: 70
Study 30875313 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD5RC (5.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Number of subjects: 70
Study 29191194 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine (HM) services utilization
Number of subjects: 500
Study 29191194 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for using HM
Number of subjects: 500
Study 29191194 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of HM use
Number of subjects: 500
Study 29191194 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic status influence on HM use
Number of subjects: 500
Study 27614789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (2mL diluted at 20% in 250mL saline) infusion
Number of subjects: 296
Study 27614789 — intervention group
Group type: COMPARATOR
Intervention: Saline (250mL) infusion
Number of subjects: 296
Study 24856748 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure cuff (inflated to 150 mm Hg)
Number of subjects: 38
Study 24856748 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 38
Study 22562540 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine topical spray
Number of subjects: 129
Study 22562540 — intervention group
Group type: COMPARATOR
Intervention: Distilled water topical spray
Number of subjects: 129
Study 20165986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy comprising intravenous application of platinum and paclitaxel
Number of subjects: 573
Study 20165986 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroscopically complete resection
Number of subjects: 573
Study 20165986 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease of 0.1-1 cm and residual tumor of >1 cm
Number of subjects: 573
Study 17684064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal pacing
Number of subjects: 42
Study 17684064 — intervention group
Group type: COMPARATOR
Intervention: Control pacing
Number of subjects: 42
Study 16273808 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish RA Combination Therapy Trial (FIN-RACo)
Number of subjects: 0
Study 16273808 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Finland RA Database
Number of subjects: 0
Study 12421195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 micro g. kg‐1. min‐1) continuously after induction of anesthesia until 18 h after CPB
Number of subjects: 40
Study 12421195 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine 0.25% [(body height (cm) - 100). 10-1=ml.h-1] for the whole study period
Number of subjects: 40
Study 12421195 — intervention group
Group type: COMPARATOR
Intervention: Control group (NaCl 0.9%) in a time-matched fashion
Number of subjects: 40
Study 9866364 — intervention group
Group type: EXPERIMENTAL
Intervention: New bed utilization program
Number of subjects: 103
Study 9866364 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation (control)
Number of subjects: 103
Study 9866364 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implementation (intervention)
Number of subjects: 103
Study 8554435 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed intrauterine insemination (IUI) without hyperstimulation
Number of subjects: 0
Study 8554435 — intervention group
Group type: COMPARATOR
Intervention: Sexual intercourse
Number of subjects: 0
Study 2687355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol
Number of subjects: 26
Study 31606605 — intervention group
Group type: EXPERIMENTAL
Intervention: New fissure-attached nodules
Number of subjects: 949
Study 31606605 — intervention group
Group type: EXPERIMENTAL
Intervention: New fissure-attached malignant nodules
Number of subjects: 949
Study 31606605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall nodules detected
Number of subjects: 949
Study 28078617 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 105
Study 28078617 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 105
Study 28429117 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Number of subjects: 75
Study 28429117 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 75
Study 25761503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 743
Study 25761503 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 743
Study 23281694 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 14
Study 23281694 — intervention group
Group type: COMPARATOR
Intervention: 308-nm excimer lamp
Number of subjects: 14
Study 21415357 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women diagnosed with CIN3+ (n = 448)
Number of subjects: 1278
Study 21415357 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women with normal Pap
Number of subjects: 1278
Study 21415357 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women with abnormal Pap
Number of subjects: 1278
Study 21415357 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related trends
Number of subjects: 1278
Study 18211117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and dimenhydrinate 40 mg three times daily for 4 weeks
Number of subjects: 66
Study 18211117 — intervention group
Group type: COMPARATOR
Intervention: Betahistine 12 mg three times daily for 4 weeks
Number of subjects: 66
Study 16608150 — intervention group
Group type: EXPERIMENTAL
Intervention: Real beer (mean breath alcohol concentration of .115 g%)
Number of subjects: 61
Study 16608150 — intervention group
Group type: COMPARATOR
Intervention: Placebo beer
Number of subjects: 61
Study 12915338 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 to 3000 mg/day
Number of subjects: 0
Study 12915338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10789176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with sponge anesthesia and intraocular injection of 0.15 ml lidocaine 1%
Number of subjects: 186
Study 10789176 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar injection of 6 ml Xylonest 2%
Number of subjects: 186
Study 8795476 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine patch (Transderm, 0.05 mg/h)
Number of subjects: 12
Study 8795476 — intervention group
Group type: COMPARATOR
Intervention: Placebo skin patch
Number of subjects: 12
Study 1295415 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g OGTT
Number of subjects: 56
Study 1295415 — intervention group
Group type: COMPARATOR
Intervention: 75g OGTT
Number of subjects: 56
Study 6432839 — intervention group
Group type: EXPERIMENTAL
Intervention: Single modified Thayer-Martin triplate
Number of subjects: 172
Study 6432839 — intervention group
Group type: EXPERIMENTAL
Intervention: Two swabs from each site (one for standard plate, one for triplate)
Number of subjects: 172
Study 6432839 — intervention group
Group type: COMPARATOR
Intervention: Triplate method
Number of subjects: 172
Study 30905926 — intervention group
Group type: COMPARATOR
Intervention: Insulin group
Number of subjects: 80
Study 29131799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 147
Study 29131799 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 147
Study 26952590 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg oral d-amphetamine
Number of subjects: 65
Study 26952590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 23396551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (6 months)
Number of subjects: 78
Study 23396551 — intervention group
Group type: COMPARATOR
Intervention: Traditional anti-hypertensive therapy (Control)
Number of subjects: 78
Study 22125196 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy Crohn's Disease Activity Index (CECDAI)
Number of subjects: 62
Study 20061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 25
Study 20061429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18059581 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW) consisting of two sets of 30-breath manoeuvres with an inspiratory pressure-threshold load equivalent to 40% maximum inspiratory mouth pressure
Number of subjects: 10
Study 18059581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) trial with inspiratory pressure-threshold load equivalent to 15% maximum inspiratory mouth pressure
Number of subjects: 10
Study 18059581 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no IM warm-up)
Number of subjects: 10
Study 15855584 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroQuick (NQT)
Number of subjects: 348
Study 15855584 — intervention group
Group type: COMPARATOR
Intervention: Medoc warm TPT
Number of subjects: 348
Study 15855584 — intervention group
Group type: COMPARATOR
Intervention: Medoc cold TPT
Number of subjects: 348
Study 15855584 — intervention group
Group type: COMPARATOR
Intervention: TipTherm
Number of subjects: 348
Study 15855584 — intervention group
Group type: COMPARATOR
Intervention: Tuning fork
Number of subjects: 348
Study 11994349 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg DNG
Number of subjects: 25
Study 11994349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg DNG
Number of subjects: 25
Study 11994349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DNG
Number of subjects: 25
Study 11994349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cyproterone acetate
Number of subjects: 25
Study 11994349 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 9705044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (up to 10 mg)
Number of subjects: 60
Study 9705044 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (up to 20 mg)
Number of subjects: 60
Study 9705044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Amlodipine and Lisinopril
Number of subjects: 60
Study 9705044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 60
Study 9705044 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 60
Study 7602436 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about legal problems
Number of subjects: 438
Study 7602436 — intervention group
Group type: COMPARATOR
Intervention: No legal factors
Number of subjects: 438
Study 7602436 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal circumstances
Number of subjects: 438
Study 2142292 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 100
Study 2142292 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 100
Study 2142292 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol after a prior single administration of prednisone
Number of subjects: 100
Study 2142292 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenaline
Number of subjects: 100
Study 2142292 — intervention group
Group type: EXPERIMENTAL
Intervention: isotonic saline solution
Number of subjects: 100
Study 2142292 — intervention group
Group type: EXPERIMENTAL
Intervention: vasoconstriction
Number of subjects: 100
Study 688256 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m2/day by iv push on Days 1‐5 every 4 weeks, followed by cyclophosphamide (C) at a dose of 400 mg/m2 and adriamycin (A) at a dose of 40 mg/m2 upon progression or renal toxic effects.
Number of subjects: 41
Study 688256 — intervention group
Group type: COMPARATOR
Intervention: C‐A (cyclophosphamide and adriamycin) at a dose of 400 mg/m2 and 40 mg/m2 respectively, given by iv push on Day 1 every 4 weeks.
Number of subjects: 41
Study 688256 — intervention group
Group type: COMPARATOR
Intervention: CAP‐I (C‐A plus concurrent P at 40 mg/m2 by IV push on Day 1 every 4 weeks).
Number of subjects: 41
Study 31324214 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric heating moxibustion
Number of subjects: 40
Study 31324214 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 40
Study 28923098 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib monotherapy (4 mg once daily)
Number of subjects: 584
Study 28923098 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib + MTX (4 mg once daily + MTX administered once weekly)
Number of subjects: 584
Study 23456731 — intervention group
Group type: EXPERIMENTAL
Intervention: Yun-cai tea
Number of subjects: 60
Study 23456731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23129823 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 11
Study 23129823 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 11
Study 23129823 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 11
Study 20674888 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoupling (DC)
Number of subjects: 42
Study 20674888 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 42
Study 18452445 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-treated patients with lifetime history of rapid cycling (RC)
Number of subjects: 359
Study 18452445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary care treated patients with lifetime history of rapid cycling (RC)
Number of subjects: 359
Study 18452445 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-treated patients with lifetime history of RC
Number of subjects: 359
Study 18452445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary care treated patients with lifetime history of RC
Number of subjects: 359
Study 18452445 — intervention group
Group type: COMPARATOR
Intervention: Tertiary care treated subjects with lifetime history of RC
Number of subjects: 359
Study 15848574 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 720 mg b.i.d. (equimolar to MMF 1000 mg b.i.d.)
Number of subjects: 237
Study 15848574 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 450 or 432 mg/m2 b.i.d. for children
Number of subjects: 237
Study 15848574 — intervention group
Group type: COMPARATOR
Intervention: MMF (< or =1000 mg b.i.d.)
Number of subjects: 237
Study 11888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 5 microg/kg followed by 0.3 microg/kg per hour infusion
Number of subjects: 80
Study 11888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 3 microg/kg followed by 0.3 microg/kg per hour infusion
Number of subjects: 80
Study 11888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg/kg followed by 0.3 microg/kg per hour infusion
Number of subjects: 80
Study 11888226 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% bolus and continuous infusion
Number of subjects: 80
Study 11888226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (all doses)
Number of subjects: 80
Study 11888226 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 80
Study 9498511 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic/antioxidant therapy (folate, mannitol, low-dose isoproterenol)
Number of subjects: 20
Study 9498511 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 20
Study 9498511 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic/antioxidant therapy group
Number of subjects: 20
Study 18475395 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline
Number of subjects: 300
Study 18475395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 2194935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laboratory-clinical research settings
Number of subjects: 0
Study 2194935 — intervention group
Group type: COMPARATOR
Intervention: Traditional laboratory research settings
Number of subjects: 0
Study 2194935 — intervention group
Group type: COMPARATOR
Intervention: Clinical research settings
Number of subjects: 0
Study 353464 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (2 sugar-coated tablets 70 mg three times daily)
Number of subjects: 57
Study 353464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31030266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day regimen of antimicrobial prophylaxis
Number of subjects: 480
Study 31030266 — intervention group
Group type: COMPARATOR
Intervention: 3-day regimen of antimicrobial prophylaxis
Number of subjects: 480
Study 27231236 — intervention group
Group type: EXPERIMENTAL
Intervention: High Five for Kids intervention (intensive 1-year intervention followed by a 1-year maintenance period)
Number of subjects: 441